See every side of every news story
Published loading...Updated

Bayer posts smaller than expected drop in Q1 profits

  • Bayer announced that its adjusted earnings for the first quarter of 2025 fell less sharply than expected, with the update released from its Frankfurt headquarters.
  • This result was driven by robust sales of newly launched medications, which compensated for a 16% decline in revenue from its U.S.-delayed soy and cotton seed products.
  • Bayer's quarterly adjusted EBITDA fell 7.4% to 4.09 billion euros, surpassing a consensus estimate of 3.75 billion euros, while the company cut 2,000 full-time positions and reduced managerial roles.
  • CEO Bill Anderson faces investor pressure to reverse a projected third consecutive annual decline in operating income for 2025 amid ongoing costly U.S. Roundup litigation and increased legal provisions.
  • Bayer confirmed its 2025 earnings outlook, plans to petition the U.S. Supreme Court to limit litigation claims, and expects to manage the impact of potential trade tariffs on pharmaceutical shipments.
Insights by Ground AI
Does this summary seem wrong?

19 Articles

All
Left
Center
3
Right
2
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

entwicklungsstadt berlin broke the news in on Monday, May 12, 2025.
Sources are mostly out of (0)